WO2005062949A3 - Method for treating hepatitis virus infection - Google Patents

Method for treating hepatitis virus infection Download PDF

Info

Publication number
WO2005062949A3
WO2005062949A3 PCT/US2004/043414 US2004043414W WO2005062949A3 WO 2005062949 A3 WO2005062949 A3 WO 2005062949A3 US 2004043414 W US2004043414 W US 2004043414W WO 2005062949 A3 WO2005062949 A3 WO 2005062949A3
Authority
WO
WIPO (PCT)
Prior art keywords
virus infection
hepatitis virus
modified
hepatitis
effective amount
Prior art date
Application number
PCT/US2004/043414
Other languages
French (fr)
Other versions
WO2005062949A2 (en
Inventor
Lawrence M Blatt
Original Assignee
Intermune Inc
Lawrence M Blatt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc, Lawrence M Blatt filed Critical Intermune Inc
Publication of WO2005062949A2 publication Critical patent/WO2005062949A2/en
Publication of WO2005062949A3 publication Critical patent/WO2005062949A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides methods of treating a hepatitis virus infection, particularly a hepatitis C virus infection, the method generally involving administering to an individual having a hepatitis virus infection an effective amount of a Type I interferon receptor agonist that is not modified with a poly(ethylene glycol) (PEG) moiety, for a period of time sufficient to reduce serum viral load to undetectable levels; followed by administering an effective amount of a Type I interferon receptor agonist that is modified with a PEG moiety, for a period of time sufficient to achieve a sustained viral response.
PCT/US2004/043414 2003-12-23 2004-12-22 Method for treating hepatitis virus infection WO2005062949A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53259903P 2003-12-23 2003-12-23
US60/532,599 2003-12-23

Publications (2)

Publication Number Publication Date
WO2005062949A2 WO2005062949A2 (en) 2005-07-14
WO2005062949A3 true WO2005062949A3 (en) 2006-03-30

Family

ID=34738814

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/043414 WO2005062949A2 (en) 2003-12-23 2004-12-22 Method for treating hepatitis virus infection

Country Status (1)

Country Link
WO (1) WO2005062949A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2815927T3 (en) 2003-12-10 2021-03-31 Nektar Therapeutics Compositions comprising two different populations of polymer-active agent conjugates
WO2006016657A1 (en) 2004-08-11 2006-02-16 Chugai Seiyaku Kabushiki Kaisha Drug for treating or preventing hcv infection
CA2652333A1 (en) * 2006-05-16 2007-11-22 Tokyo Metropolitan Organization For Medical Research Pharmaceutical composition for treating or preventing hcv infection
WO2010061881A1 (en) 2008-11-26 2010-06-03 中外製薬株式会社 Oligoribonucleotide or peptide nucleic acid capable of inhibiting activity of hepatitis c virus
WO2011014882A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS
ES2572329B1 (en) 2011-10-21 2017-08-24 Abbvie Inc. COMBINATION OF AT LEAST TWO DIRECT ACTION AND RIBAVIRIN AGENTS, BUT NOT INTERFERONED, FOR USE IN THE HCV TREATMENT
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
BR112014005617A2 (en) 2011-10-21 2017-06-13 Abbvie Inc combination treatment (for example with abt-072 or abt -333) of daas for use in the treatment of hcv
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US6250469B1 (en) * 1998-03-26 2001-06-26 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
US20020147160A1 (en) * 2001-01-22 2002-10-10 Balkrishen Bhat Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
US6472373B1 (en) * 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US20030055013A1 (en) * 2001-09-20 2003-03-20 Schering Corporation HCV combination therapy
US20030187018A1 (en) * 2002-02-01 2003-10-02 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US6472373B1 (en) * 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6250469B1 (en) * 1998-03-26 2001-06-26 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
US20020147160A1 (en) * 2001-01-22 2002-10-10 Balkrishen Bhat Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
US20030055013A1 (en) * 2001-09-20 2003-03-20 Schering Corporation HCV combination therapy
US20030187018A1 (en) * 2002-02-01 2003-10-02 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ARMENDARIZ-BORUNDA ET AL: "A Pilot Study of a Novel Anti-inflammatory and Anti-fibrotic Agent, Pirfenidone, in Patients with Liver Cirrosis", HEPATOLOGY (54TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES, vol. 38, no. 4 (SUPP 1), 24 October 2003 (2003-10-24) - 28 October 2003 (2003-10-28), XP002995112 *
HADZIYANNIS ET AL: "Peginterferon-alpha2a (40kDa) for chronic hepatitis C", EXPERT OPINION ON PHARMACOLOGY, vol. 4, no. 4, April 2003 (2003-04-01), pages 541 - 551, XP008060227 *
LINDSAY ET AL: "A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C", HEPATOLOGY, vol. 34, no. 2, August 2001 (2001-08-01), pages 395 - 403, XP002995113 *
POCKROS ET AL: "The safety and tolerability of daily infergen plus ribavirin in the treatment of naive chronic hepatitis C patients", JOURNAL OF VIRAL HEPATITIS, vol. 10, no. 1, January 2003 (2003-01-01), pages 55 - 60, XP002995111 *
SARACCO ET AL: "Therapy of chronic hepatitis C: a critical review", CURRENT DRUG TARGETS INFECTIOUS DISORDERS, vol. 3, no. 1, March 2003 (2003-03-01), pages 25 - 32, XP008060224 *
SHERMAN ET AL: "Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial", HEPATOLOGY, vol. 27, no. 4, April 1998 (1998-04-01), pages 1128 - 1135, XP002905772 *

Also Published As

Publication number Publication date
WO2005062949A2 (en) 2005-07-14

Similar Documents

Publication Publication Date Title
WO2007084413A3 (en) Methods for treating hepatitis c
RU2010139908A (en) RSV, PIV AND OTHER RESPIRATORY VIRUSES MODULATION USING RNAI AND ITS APPLICATION
TW200602064A (en) Nucleoside derivatives for treating hepatitis C virus infection
WO2001077091A3 (en) Ns5b hcv polymerase inhibitors
EA200701450A1 (en) RNKI MODULATION RSV AND ITS THERAPEUTIC APPLICATION
WO2001074768A3 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
WO2005062949A3 (en) Method for treating hepatitis virus infection
EA200300023A1 (en) 3'-PROCEDURES 2'-DEOXY-β-L-NUCLEOSIDES
WO2004014852A3 (en) Iminothiazolidinones as inhibitors of hcv replication
WO2007070600A3 (en) N-(5-membered heteroaromatic ring)-amido anti-viral compounds
WO2005054430A3 (en) Hepatitis c virus inhibitors
EA200501689A1 (en) CONNECTIONS AS HEPATITIS C VIRUS INHIBITORS
EP2340830A3 (en) Hepatitis C Virus Inhibitors
WO2003079757A3 (en) Hiv therapeutic
WO2007084435A3 (en) Methods for treating hepatitis c
JP2011519414A5 (en)
WO2003093290A3 (en) Nucleoside derivatives for treating hepatitis c virus infection
WO2004028481A3 (en) Nucleoside derivatives for treating hepatitis c virus infection
WO2008057871A3 (en) Inhibitors of hepatitis c virus
WO2005013917A3 (en) Combination therapy for treating alphavirus infection and liver fibrosis
WO2004078127A3 (en) Continuous delivery methods for treating hepatitis virus infection
WO2003015708A3 (en) Composition and method for treating hiv infection
WO2005067454A3 (en) Combination therapy for treating hepatitis c virus infection
DK1284720T3 (en) L-FMAU for the treatment of hepatitis delta virus infection
WO2005110455A3 (en) Combination therapy for treating hepatitis virus infection

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase